Alembic Pharmaceuticals Posts 29% Profit Surge in Q4

Alembic Pharmaceuticals Ltd reported a 29% increase in Q4 net profit, reaching Rs 202.7 crore due to revenue growth across segments. The company's revenue from operations increased to Rs 1,847.72 crore. Alembic entered the US branded business, launching Pivya. A dividend of Rs 12 per share was recommended.

Alembic Pharmaceuticals Ltd on Friday announced a 29 percent increase in consolidated net profit for the fourth quarter, reaching Rs 202.7 crore. This growth was driven by consistent revenue expansion across various segments.

The company's consolidated revenue from operations for the quarter ending March 31 was Rs 1,847.72 crore, up from Rs 1,769.64 crore in the previous fiscal's same period. Total expenses for the quarter rose to Rs 1,730.94 crore from Rs 1,591.22 crore a year ago.

Managing Director Pranav Amin credited disciplined execution, operational delivery, and long-term growth investments for the profit rise. Alembic marked its entry into the US branded sector by launching Pivya. For the fiscal year ended March 31, 2026, the board has recommended a dividend of Rs 12 per share.